

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

**APPLICATION NUMBER: 20-678/S003**

**ENVIRONMENTAL ASSESSMENT AND/OR FONSI**

**Baxter**

March 31, 2000

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Drug Evaluation II  
Division of Metabolism and Endocrine Drug Products, HFD-510  
Document Control Room 14B-19  
5600 Fishers Lane  
Rockville, MD 20857-1706

**Re: NDA 19-520/S-018: Travasol<sup>®</sup> -sulfite-free (Amino Acid) in Dextrose Injection  
in Quick-Mix<sup>®</sup> Dual Chamber PL 146 Plastic Container**

**NDA 20-147/S-006: Travasol<sup>®</sup> -sulfite-free (Amino Acid) with Electrolytes in  
Dextrose Injection in Quick-Mix<sup>®</sup> Dual Chamber PL 146 Plastic Container**

**NDA 20-678/S-003: Clinimix E<sup>™</sup> sulfite-free (Amino Acid with Electrolytes  
in Dextrose with Calcium) Injections in Clarity<sup>™</sup> Dual Chamber Container**

**NDA 20-734/S-003: Clinimix E sulfite-free (Amino Acid in Dextrose) Injections**

**Minor Amendment - Pediatric Labeling Statements**

Dear Colleague:

Baxter Healthcare Corporation is submitting this minor amendment to each of the above referenced pediatric labeling supplements in response to a request by the Agency for additional administrative requirements to complete the review package. The following four Attachments should provide sufficient information to complete the review of the Pediatric Labeling Supplements:

**Attachment 1. Environment Assessment - Request for categorical exclusion.**

**Attachment 2. Patent Certification.**

**Attachment 3 Debarment Certification.**

**Attachment 4 Financial Disclosure – Justification for not certifying or disclosing  
financial information on investigators.**

MAR 31 2000

# **Baxter**

A completed 356h application form and a User Fee form are attached to this cover letter.

If you have any questions, please contact me or Lisa Skeens, PhD at (847) 270-2577.

Sincerely,



for

Marcia Marconi  
Vice President, Regulatory Affairs  
phone: (847) 270-4637  
fax: (847) 270-4668

cc: Steve McCort

APPEARS THIS WAY  
ON ORIGINAL

MAR 31 2000

## ATTACHMENT 1

### ENVIRONMENT ASSESSMENT – REQUEST FOR CATEGORICAL EXCLUSION

**1. Date**

March 31, 2000

**2. Name of Applicant**

Baxter Healthcare Corporation

**3. Address**

I.V. Systems Division (Headquarters):      Route 120 and Wilson Rd.  
Round Lake, IL 60073

**4. Description of Proposed Action; Request for Categorical Exclusion**

Baxter Healthcare Corporation has filed a supplement to NDA 20-147: Travasol® –sulfite-free (Amino Acid) with Electrolytes in Dextrose Injection in Quick-Mix® Dual Chamber PL 146® Plastic Container pursuant to section 505(b)(1) of the Food, Drug and Cosmetic Act for approval to add pediatric use statements to the labeling.

Travasol® –sulfite-free (Amino Acid) with Electrolytes in Dextrose Injection in Quick-Mix® Dual Chamber PL 146® Plastic Container is a sterile, nonpyrogenic, hypertonic solution of essential and nonessential amino acids in one chamber and Dextrose Injection, USP in the other chamber of a dual chamber bag. The formulation contains drug substances approved in Baxter's other amino acid products.

MAR 31 2000

The chemical names, chemical abstracts service (CAS) registration numbers, molecular formulae and molecular weights for all the components which comprise the admixed drug product are listed in Table 1 on the next page.

The drug product will be manufactured at Baxter's North Cove, North Carolina facility located at:

Baxter Healthcare Corporation  
North Cove, North Carolina Facility  
Highway 221 North  
Marion, North Carolina 28752

MAR 31 2000

Table 1

Contents of Travasol® sulfite-free (Amino Acid) with Electrolytes  
in Dextrose Injection

Alanine, USP	L- $\alpha$ -aminopropionic acid	56-41-7	$C_3H_7NO_2$	89.09
Arginine, USP	2-amino-5-guanidinovaleric acid	74-79-3	$C_6H_{14}N_4O_2$	174.20
Glycine, USP	aminoacetic acid	56-40-6	$C_2H_5NO_2$	75.07
Histidine, USP	$\alpha$ -amino-4 (or 5) imidazolepropionic acid	71-00-1	$C_6H_9N_3O_2$	155.16
Isoleucine, USP	2-amino-3-methylvaleric acid	73-32-5	$C_6H_{13}NO_2$	131.18
Leucine, USP	2-amino-4-methylvaleric acid	61-90-5	$C_6H_{13}NO_2$	131.18
Lysine Hydrochloride, USP	L-2,6-diaminohexanoic acid hydrochloride	56-87-1	$C_6H_{14}N_2O_2 \cdot HCl$	182.65
Methionine, USP	2-amino-4-methylthiobutanoic acid	63-68-3	$C_5H_{11}NO_2S$	149.22
Phenylalanine, USP	$\alpha$ -amino- $\beta$ -phenylpropionic acid	63-91-2	$C_9H_{11}NO_2$	165.19
Proline, USP	2-pyrrolidine carboxylic acid	147-85-3	$C_5H_9NO_2$	115.13
Threonine, USP	2-amino-3-hydroxybutyric acid	72-19-5	$C_4H_9NO_3$	119.12
Tryptophan, USP	2-amino-3-indolylpropanoic acid	73-22-3	$C_{11}H_{12}N_2O_2$	204.23
Tyrosine, USP	$\alpha$ -amino-p-hydroxyhydrocinnamic acid	60-18-4	$C_9H_{11}NO_3$	181.19
Valine, USP	2-aminoisovaleric acid	72-18-4	$C_5H_{11}NO_2$	117.15
}				
Dextrose USP	d-glucose monohydrate	5996-10-1	$C_6H_{12}O_6 \cdot H_2O$	198.17

MAR 31 2000


Request for Categorical Exclusion

The applicant requests a categorical exclusion from the preparation of an Environmental Assessment as provided under 21 CFR §25.31 (c).

Approval of the pediatric labeling supplement is not expected to alter significantly the concentration or distribution of amino acids, their metabolites, or degradation products in the environment. Furthermore, to the best of the applicant's knowledge, there are no extraordinary circumstances, as defined in 21 CFR 25.15(d), that would indicate that the approval of this pediatric labeling supplement could affect the quality of the human environment.

**5. Certification**

The undersigned official certifies that to the best of Baxter's knowledge the information presented here is true, accurate and complete

  
Marcia Marconi, Vice President  
Regulatory Affairs

March 31, 2000

APPEARS THIS WAY  
ON ORIGINAL

MAR 31 2000

**MEMORANDUM**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH**

DATE: April 4, 2000

FROM: Elsbeth Chikhale, Ph.D.  
Chemistry Reviewer, ONDC, DNDC II, HFD-820

SUBJECT: Environmental Assessment

TO: File for NDAs 19-520/S-018, 20-147/S-006, 20-678/S-003, 20-734/S-003

The firm requested a categorical exclusion to the above supplemental NDAs in an amendment to the NDA supplements dated March 31, 2000. As provided for under 62 FR 145, section 25.31(c) and (d), the above supplements qualify for a categorical exclusion, based upon the amount of waste entering the environment will not significantly alter the concentration of amino acids, their metabolites, or degradation products.

*/S/*

*4/4/00*

~~Elsbeth Chikhale, Ph.D.  
Chemistry Reviewer  
ONDC, DNDC II, HFD-820~~

~~Duu-Gong Wu, Ph.D.  
Chemistry Team Leader  
ONDC II, DNDC II, HFD-820~~

cc:

NDAs 19-520/S-018, 20-147 — 20-678/S-003, 20-734/S-003  
HFD-510/Division Files  
HFD-820/DWu/EChikhale  
HFD-510/CSO/McCort

**APPEARS THIS WAY  
ON ORIGINAL**